{"name":"Mast Therapeutics, Inc.","slug":"mast-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ANX-514","genericName":"ANX-514","slug":"anx-514","indication":"Other","status":"phase_1"},{"name":"ANX-188 Supratherapeutic dose","genericName":"ANX-188 Supratherapeutic dose","slug":"anx-188-supratherapeutic-dose","indication":"Other","status":"phase_1"},{"name":"ANX-188 Therapeutic Dose","genericName":"ANX-188 Therapeutic Dose","slug":"anx-188-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"poloxamer 188","genericName":"poloxamer 188","slug":"poloxamer-188","indication":"Other","status":"marketed"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CoFactor (ANX-510)","genericName":"CoFactor (ANX-510)","slug":"cofactor-anx-510","indication":"Rare metabolic or genetic disorders associated with cofactor deficiency (specific indication not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"ANX-514","genericName":"ANX-514","slug":"anx-514","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANX-188 Supratherapeutic dose","genericName":"ANX-188 Supratherapeutic dose","slug":"anx-188-supratherapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ANX-188 Therapeutic Dose","genericName":"ANX-188 Therapeutic Dose","slug":"anx-188-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CoFactor (ANX-510)","genericName":"CoFactor (ANX-510)","slug":"cofactor-anx-510","phase":"phase_3","mechanism":"CoFactor (ANX-510) is a cofactor replacement therapy designed to restore deficient cofactor levels in patients with certain metabolic or genetic disorders.","indications":["Rare metabolic or genetic disorders associated with cofactor deficiency (specific indication not publicly detailed)"],"catalyst":""},{"name":"poloxamer 188","genericName":"poloxamer 188","slug":"poloxamer-188","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQSXZhVFJiWFhvZ0tyb3E0SG41VFBVRFpNay1LcGZmYWNHaG5mX0RoRW5nOEVwWmlDcVRaVE5HaElTTVJOWDdvbG5TbGpEQU1UQkluYml6LUJ2bjA1dS1GOXc4XzloMFhVWmxvVlByMi1oWG1QbENkZVYzSTM1T1pFaEQ2dFBDTFFGNGVMcjVyZm1yck8ycXlNNkw5WUVTS1Q4RnNBVGhmYmFkZkpXcHotMXpRVml2d1QyMTRPNTM3Vk9sbklW?oc=5","date":"2026-03-24","type":"trial","source":"AD HOC NEWS","summary":"Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS","headline":"Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE90Q1MzWlhVZVVCY2FOb0kyNFlwWDZIRllkQ05aVmpQY3JITmJIeUVmTzNGV3ZkcEU3NVFnNkxwX0tEcjF0dGdYRU93TlNkWGQwdV9pNTk1a1ByVnJjU2ZqR2QzUWl1dGRlR0hQaERn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Jasper Therapeutics Inc (JSPR) - Stock Titan","headline":"If You Invested $1,000 in Jasper Therapeutics Inc (JSPR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNMTgyRkY5ejNzaWYwbUtnTDh1Rm14OXlXckh3clIzcUw3dWlueXRzMWp3RmV5WC1QOGFjSjJRYkxZd3RsNERySTAzZ2Nyejl6a1cybFpqb0Itd2FCSEFuMEp5OG5DQTAxN3FHYy00MlhrY0MyOWVxeWlJcC1MSy1TWFdqV0M1bmpuNFVwc01LWGt2Rm96WHBSbA?oc=5","date":"2026-02-10","type":"trial","source":"Yahoo Finance","summary":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Yahoo Finance","headline":"Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Ty","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRXRNaEpCNE85a0xwamJfajJ4VXVDajRxdkpSZ1FqbkdJR3psSURURFpuX1VfY1MybTVEYkdDaUVqVGJuWjNOVEhYcVdkWXdYSElodTdCVkNzY2pJNzBoaFVOQXNkZ1NqZzJrZldvZVdDTXNySk5EWF9QRTRKSW1zc0xhQUxya2w1bDA1RTRTLW5HdExJS0RpeXFWbGI?oc=5","date":"2025-12-03","type":"trial","source":"statnews.com","summary":"Hair loss drug succeeds in Phase 3, but data underwhelms experts - statnews.com","headline":"Hair loss drug succeeds in Phase 3, but data underwhelms experts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNZUdrMzNiSDVoRE92S3Nfc2tfR2tKc09lRDdyUXBJZnQ4clk1THpYOUJ6bzFjTklzZy1PSWdXbkdPUUFkZzJoYnpELVBERzZWWmhON19veFJBeGhEYkxwWVhzT1p3SGVjOEIwd2JnSG1GZWZDR2JkQ0hXcVpWRDBxek1WX1NiM1B0SzF4OF82Z2dJM2lPZWV1NEptVXpmUmptLW1ISlpUQQ?oc=5","date":"2025-10-30","type":"pipeline","source":"statnews.com","summary":"How Moderna, the company that helped save the world, unraveled - statnews.com","headline":"How Moderna, the company that helped save the world, unraveled","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE50Q0VNeElPNnFXRXM3WkFrbGVsQkhwWWtxRXBTaF9iOUp2ZlY2QUFla1F0MFgwNEJBMDZRRHBxbmd5TFNTdVJNa2c2eFNvTG1PX0w2QjlyN3E3WTljcF9veEZmbnR5RjlEa1VyNXRRT3A?oc=5","date":"2025-10-25","type":"pipeline","source":"The Times","summary":"Ipsen, AstraZeneca and Greywolf lead winners at Pharma Industry Awards UK 2025 in association with Kuehne + Nagel - The Times","headline":"Ipsen, AstraZeneca and Greywolf lead winners at Pharma Industry Awards UK 2025 in association with Kuehne + Nagel","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTFlMSjhVM2F6WDc2LWJCQndSMUFEQXEyWk05dnZ0MEItSi0wUU5DNERZSG04Mm1mNDVZUU93MkZQVmZQTTNzd3Vvbm9kdmJobzZTSkl0QlpGa3RsdU0yOVlud0lXd254ZjU4bUt6ZG9HeUtMWklELUpFbVAwN3QzZUlIMV9zMEIxdVJodjYyMzFFRzRGVjZkaWdqZlU?oc=5","date":"2024-03-04","type":"pipeline","source":"insiderfinancial.com","summary":"Mast Therapeutics Inc (NYSEMKT:MSTX): Here's What We're Watching - insiderfinancial.com","headline":"Mast Therapeutics Inc (NYSEMKT:MSTX): Here's What We're Watching","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPSGwxQTg0R3JIS1ZRcWZld202RnZpdk5NcURVSjdpNnJhMWJSNUh0cS13cncxVlpkVktrc1p4MjFGcHphNDJId0hkWElCaGFuSjNQVWsxaTNucWx5ejg4RmxjV2tKbzBjR3hfdGlvQTdIMGNwS3FhRDBUY1VXU0xKYktxR1NydFljeFBFNTdvS3RfRVRuVHFUb001MFRrZw?oc=5","date":"2018-03-12","type":"deal","source":"Fierce Biotech","summary":"Savara abandons drug behind last year’s reverse merger with Mast - Fierce Biotech","headline":"Savara abandons drug behind last year’s reverse merger with Mast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPY0hESzBrZ3ZhMHlJbXUzZ0ViRThPUDNQeW1MQV9uOVF2QkNPVHpZeENmZ0RWbnJiOE9YYzFNdVlhZUpCMU1KVkRMZmJsLXRwNHB2LW1URm1pekdYSTFodkRaWWFGUXVSei1rdFY0N2RkTS0wUzE5eVlFeFkybnVaNXctLS1lQmxJclItR29aVWYwcm9YY0hpbzJWR2Mxaks0alhTSXZKeFVWY1NNNlgwS05tZw?oc=5","date":"2017-04-27","type":"deal","source":"PR Newswire","summary":"Savara Announces Closing Of Merger With Mast Therapeutics - PR Newswire","headline":"Savara Announces Closing Of Merger With Mast Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNR1JsTl9ZTktEbFpxMTlxQ0ZMcnp2ZC1JMHF4UHRsa3VzZ3NyaUNFVWFoYmwtMmhidGxvaVVsMHNlWDRLTm1wUHZyT3lObGtOeTN0QWJ1eTNCdGs0a19CeENVLWlUTjZuRUpkOVRQcGZRYXoxMnY4SnZQQzktYW51Y3BpbElpUGdlNlR3YXQzdWxIN0JYOUhrN2hkVG9tempFQlMzV3BNSy1ya2JXRnhYSUlCZw?oc=5","date":"2017-03-06","type":"trial","source":"Drug Delivery Business","summary":"Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution - Drug Delivery Business","headline":"Mast Therapeutics subsidiary advances trial for inhaled sodium nitrite solution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE4yZHU2a1FWS0dnU1ZXam5MUlFNU3YtOW41Y2tDa3pfTjc4cGhFdjhMeTVxQXdNM3FacFpVTEd0WGdmTjBTYl9LaHM2R2kzQ2FyQllYVjZ4Z20td29JNnZwV1FGQU5hM0c5VkdZalVEY1NuU0tuOWlB?oc=5","date":"2017-01-09","type":"deal","source":"MassDevice","summary":"Mast Therapeutics, Savara ink merger deal - MassDevice","headline":"Mast Therapeutics, Savara ink merger deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOd0lDc3ROYXF6aWhkRkhYX1RxQ2JyVGowM1pTajdpb2FPaUNVMVJWbHo2OWpuQ2dmbmQ5Q3pzeE5wTll2eUlaS3hRZ09fYTY3Q1k1dWdfNmdqOUlleVRpdGxmZWtoOTJyLUhiSFlKRzNUZ1Nxa3hZWUFieFItbU1LcHc2MHMyWUdvRmV5dS1PZlpsTU8zcm1kSk1xX1hraEk?oc=5","date":"2014-06-10","type":"trial","source":"dicardiology.com","summary":"Mast Therapeutics Announces Positive Data in Model of Heart Failure - dicardiology.com","headline":"Mast Therapeutics Announces Positive Data in Model of Heart Failure","sentiment":"negative"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":3,"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}